Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Weekly News Recap #Phispers
1. Bms 907351
2. Bms-907351
3. Bms907351
4. Cabozantinib
5. Cometriq
6. Xl 184
7. Xl-184
8. Xl184 Cpd
1. 1140909-48-3
2. Cabozantinib Malate
3. Cabozantinib (s)-malate
4. Cabometyx
5. Cabozantinib Malate (xl184)
6. Xl184
7. Cabozantinib (s-malate)
8. Cometriq
9. Cabozantinib S-malate [usan]
10. Dr7st46x58
11. Bms907351
12. Chebi:72319
13. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate
14. Cabometyx (tn)
15. Cometriq (tn)
16. Cabozantinib Malate (jan)
17. 1-n-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2s)-2-hydroxybutanedioic Acid
18. Cabozantinib S-malate (usan)
19. Cabozantinib Malate [jan]
20. Unii-dr7st46x58
21. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
22. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
23. Xl184 Malate
24. Cabozantinib L-malate
25. Bms907351 Malate
26. Xl184(cabozantinib Malate)
27. Mls006010951
28. Chembl2103868
29. Dtxsid60915949
30. Ex-a2819
31. Mfcd20923480
32. S4001
33. 1140909-48-3 (malate)
34. Akos025401945
35. Cabozantinib S-malate [who-dd]
36. Ccg-270301
37. Cs-0201
38. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluor
39. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
40. Ac-27471
41. As-75255
42. Hy-12044
43. Smr004702755
44. Cabozantinib S-malate [orange Book]
45. Sw218093-2
46. D10095
47. Q27139901
48. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
49. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
50. (2s)-2-hydroxybutanedioic Acid; N'1-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
51. 1,1-cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4- Fluorophenyl)- Mono((2s)-2-hydroxybutanedioate)
52. Cyclopropane-1,1-dicarboxylic Acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, (s) Malate Salt
53. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Mono((2s)-2-hydroxybutanedioate)
54. N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate
55. N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2s)-2-hydroxybutanedioate
Molecular Weight | 635.6 g/mol |
---|---|
Molecular Formula | C32H30FN3O10 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 11 |
Exact Mass | 635.19152232 g/mol |
Monoisotopic Mass | 635.19152232 g/mol |
Topological Polar Surface Area | 194 Ų |
Heavy Atom Count | 46 |
Formal Charge | 0 |
Complexity | 924 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
* Renal Cell Carcinoma (RCC):
Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):
- in treatment-nave adults with intermediate or poor risk,
- in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.
* Hepatocellular Carcinoma (HCC):
Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
L01EX07
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39757
Submission : 2024-03-22
Status : Active
Type : II
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-04-17
Pay. Date : 2020-02-27
DMF Number : 34437
Submission : 2020-02-25
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39141
Submission : 2023-12-01
Status : Active
Type : II
NDC Package Code : 71796-059
Start Marketing Date : 2023-03-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39785
Submission : 2024-03-26
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38207
Submission : 2023-03-31
Status : Active
Type : II
NDC Package Code : 71796-059
Start Marketing Date : 2023-03-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39785
Submission : 2024-03-26
Status : Active
Type : II
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39757
Submission : 2024-03-22
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-04-17
Pay. Date : 2020-02-27
DMF Number : 34437
Submission : 2020-02-25
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39274
Submission : 2023-12-29
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39141
Submission : 2023-12-01
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38207
Submission : 2023-03-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-12-06
Pay. Date : 2023-03-08
DMF Number : 38057
Submission : 2023-09-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-06-08
Pay. Date : 2017-05-22
DMF Number : 31522
Submission : 2017-03-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-06-25
Pay. Date : 2019-04-22
DMF Number : 33137
Submission : 2018-09-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-03-23
Pay. Date : 2022-02-28
DMF Number : 36509
Submission : 2022-02-28
Status : Active
Type : II
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm : MIs. MSN Laboratories Private Limited, Unit-II, sv. No, 50, Kardanur (Village), ...
Date of Issue : 2019-08-05
Valid Till : 2022-05-05
Written Confirmation Number : WC-0349A3
Address of the Firm : Unit-||, Sy. No. 50, Kardanur Village, Patti/Post Patancheru Mandal,Medak Distri...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 71796-059
Start Marketing Date : 2023-03-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 48957-0121
Start Marketing Date : 2021-02-26
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65727-091
Start Marketing Date : 2023-07-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0078
Start Marketing Date : 2018-07-20
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0058
Start Marketing Date : 2017-02-06
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 55679-116
Start Marketing Date : 2012-11-15
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59057-013
Start Marketing Date : 2022-08-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59057-018
Start Marketing Date : 2024-09-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 64918-1924
Start Marketing Date : 2023-05-12
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 81955-0021
Start Marketing Date : 2012-11-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2024
Lead Product(s) : Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CABINET Ph III Final Results Reinforce Efficacy of Cabometyx in Neuroendocrine Tumors
Details : Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.
Brand Name : Cabometyx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 16, 2024
Details:
Cabometyx (Cabozantinib) tablet is a TK inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2024
Lead Product(s) : Cabozantinib,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ipsen Updates on CONTACT-02 Trial in Metastatic Castration-Resistant Prostate Cancer
Details : Cabometyx (Cabozantinib) tablet is a TK inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.
Brand Name : Cabometyx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2024
Details:
Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated for the treatment of patients with advanced pancreatic neuroendocrine tumors.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2024
Lead Product(s) : Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Exelixis Announces FDA Accepted the sNDA for Cabozantinib for Neuroendocrine Tumors
Details : Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated for the treatment of patients with advanced pancreatic neuroendocrine tumors.
Brand Name : Cabometyx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 06, 2024
Details:
The collaboration with Exelixis for the development of Cabometyx (cabozantinib S-malate) in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumor.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Exelixis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 02, 2024
Lead Product(s) : Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Exelixis
Deal Size : Undisclosed
Deal Type : Collaboration
Ipsen Expands Agreement for Cabometyx® in Neuroendocrine Tumors After CABINET Trial
Details : The collaboration with Exelixis for the development of Cabometyx (cabozantinib S-malate) in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumor.
Brand Name : Cabometyx
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 02, 2024
Details:
Kura's lead product KO-2806, which is a Ftase inhibitor got dosing of the first patient in Phase I clinical trial studies in combination with cabozantinib for the treatment of Renal Cell Carcinoma.
Lead Product(s): KO-2806,Cabozantinib
Therapeutic Area: Oncology Brand Name: KO-2806
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Lead Product(s) : KO-2806,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tenax Therapeutics Announces Global License Amendment Expanding Rights to Levosimendan
Details : Kura's lead product KO-2806, which is a Ftase inhibitor got dosing of the first patient in Phase I clinical trial studies in combination with cabozantinib for the treatment of Renal Cell Carcinoma.
Brand Name : KO-2806
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 06, 2024
Details:
Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor. It is being evaluated in combination with Cabometyx (cabozantinib) for first-line advanced renal cell carcinoma.
Lead Product(s): Nivolumab,Cabozantinib
Therapeutic Area: Oncology Brand Name: Opdivo
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Exelixis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Lead Product(s) : Nivolumab,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Exelixis
Deal Size : Not Applicable
Deal Type : Not Applicable
Opdivo® + CABOMETYX® Shows Long-Term Survival in CheckMate -9ER for Renal Cell Carcinoma
Details : Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor. It is being evaluated in combination with Cabometyx (cabozantinib) for first-line advanced renal cell carcinoma.
Brand Name : Opdivo
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 22, 2024
Details:
KO-2806 is farnesyl transferase inhibitor which demonstrated in combination with KRASG12C inhibitors to drive tumor regressions and durable responses in KRASG12C-mutantion non-small cell lung cancer (NSCLC).
Lead Product(s): KO-2806,Cabozantinib
Therapeutic Area: Oncology Brand Name: KO-2806
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Lead Product(s) : KO-2806,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KO-2806 is farnesyl transferase inhibitor which demonstrated in combination with KRASG12C inhibitors to drive tumor regressions and durable responses in KRASG12C-mutantion non-small cell lung cancer (NSCLC).
Brand Name : KO-2806
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 19, 2023
Details:
KO-2806 is farnesyl transferase inhibitor which demonstrated in combination with KRASG12C inhibitors to drive tumor regressions and durable responses in KRASG12C-mutant non-small cell lung cancer (NSCLC).
Lead Product(s): KO-2806,Cabozantinib
Therapeutic Area: Oncology Brand Name: KO-2806
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Lead Product(s) : KO-2806,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KO-2806 is farnesyl transferase inhibitor which demonstrated in combination with KRASG12C inhibitors to drive tumor regressions and durable responses in KRASG12C-mutant non-small cell lung cancer (NSCLC).
Brand Name : KO-2806
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2023
Details:
Cabometyx (Cabozantinib) tablet is a Mmultiple Rreceptor tyrosine kinases inhibitor, which is investigated for the treatment of advanced pancreatic and extra-pancreatic neuroendocrine tumors.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
Lead Product(s) : Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cabometyx (Cabozantinib) tablet is a Mmultiple Rreceptor tyrosine kinases inhibitor, which is investigated for the treatment of advanced pancreatic and extra-pancreatic neuroendocrine tumors.
Brand Name : Cabometyx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 24, 2023
Details:
Cabometyx (Cabozantinib) tablet is a multiple receptor tyrosine kinases inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Ipsen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Lead Product(s) : Cabozantinib,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Ipsen
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cabometyx (Cabozantinib) tablet is a multiple receptor tyrosine kinases inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.
Brand Name : Cabometyx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 21, 2023
RLD :
TE Code :
Brand Name : CABOZANTINIB
Dosage Form : TABLET;ORAL
Dosage Strength : 20MG
Approval Date :
Application Number : 215942
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : CABOZANTINIB
Dosage Form : TABLET;ORAL
Dosage Strength : 40MG
Approval Date :
Application Number : 215942
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : CABOZANTINIB
Dosage Form : TABLET;ORAL
Dosage Strength : 60MG
Approval Date :
Application Number : 215942
RX/OTC/DISCN :
RLD :
TE Code :
RLD : Yes
TE Code :
Brand Name : COMETRIQ
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 20MG BASE
Approval Date : 2012-11-29
Application Number : 203756
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : COMETRIQ
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 80MG BASE
Approval Date : 2012-11-29
Application Number : 203756
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : CABOMETYX
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 20MG BASE
Approval Date : 2016-04-25
Application Number : 208692
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : CABOMETYX
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 40MG BASE
Approval Date : 2016-04-25
Application Number : 208692
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : CABOMETYX
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 60MG BASE
Approval Date : 2016-04-25
Application Number : 208692
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Regulatory Info :
Registration Country : Norway
Brand Name : Cabometyx
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 20 mg
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Cabometyx
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 40 mg
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Cabometyx
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 60 mg
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Cometriq
Dosage Form :
Dosage Strength :
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Cometriq
Dosage Form :
Dosage Strength :
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Cometriq
Dosage Form : Capsule, hard
Dosage Strength : 20 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Cabometyx
Dosage Form : Film-Coated Tablets
Dosage Strength : 20mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Cabometyx
Dosage Form : Film-Coated Tablets
Dosage Strength : 40mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Cabometyx
Dosage Form : Film-Coated Tablets
Dosage Strength : 60mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Cometriq
Dosage Form : HARD CAPSULES
Dosage Strength : 20 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?